Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of intensive praziquantel administration on vaccine-specific responses among schoolchildren in Ugandan schistosomiasis-endemic islands (POPVAC A): an open-label, randomised controlled trial.
Nkurunungi G, Nassuuna J, Natukunda A, Zirimenya L, Walusimbi B, Zziwa C, Ninsiima C, Kabagenyi J, Kabuubi PN, van Dam GJ, Corstjens PLAM, Kayiwa J, Kizza M, Mutebe A, Nakazibwe E, Akello FA, Sewankambo M, Kiwanuka S, Cose S, Wajja A, Kaleebu P, Webb EL, Elliott AM; POPVAC trial team. Nkurunungi G, et al. Among authors: webb el. Lancet Glob Health. 2024 Nov;12(11):e1826-e1837. doi: 10.1016/S2214-109X(24)00280-8. Lancet Glob Health. 2024. PMID: 39424571 Free PMC article. Clinical Trial.
Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics.
Nkurunungi G, Zirimenya L, Natukunda A, Nassuuna J, Oduru G, Ninsiima C, Zziwa C, Akello F, Kizindo R, Akello M, Kaleebu P, Wajja A, Luzze H, Cose S, Webb E, Elliott AM; POPVAC trial team. Nkurunungi G, et al. BMJ Open. 2021 Feb 16;11(2):e040425. doi: 10.1136/bmjopen-2020-040425. BMJ Open. 2021. PMID: 33593767 Free PMC article.
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
Herrera C, Serwanga J, Else L, Limakatso L, Opoka D, Ssemata AS, Pillay AD, Namubiru P, Seiphetlo TB, Odoch G, Mugaba S, Seatlholo P, Alieu A, Penchala SD, Muhumuza R, Alinde B, Petkov S, O'Hagan K, Callebaut C, Seeley J, Weiss H, Khoo S, Chiodi F, Gray CM, Kaleebu P, Webb EL, Martinson N, Fox J; CHAPS. Herrera C, et al. Among authors: webb el. EBioMedicine. 2023 Jul;93:104648. doi: 10.1016/j.ebiom.2023.104648. Epub 2023 Jun 14. EBioMedicine. 2023. PMID: 37327677 Free PMC article. Clinical Trial.
Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: protocol for safety and dose-finding trial.
Abaasa A, Egesa M, Driciru E, Koopman JPR, Kiyemba R, Sanya RE, Nassuuna J, Ssali A, Kimbugwe G, Wajja A, van Dam GJ, Corstjens PLAM, Cose S, Seeley J, Kamuya D, Webb EL, Yazdanbakhsh M, Kaleebu P, Siddiqui AA, Kabatereine N, Tukahebwa E, Roestenberg M, Elliott AM. Abaasa A, et al. Among authors: webb el. Immunother Adv. 2023 Jul 20;3(1):ltad010. doi: 10.1093/immadv/ltad010. eCollection 2023. Immunother Adv. 2023. PMID: 37538934 Free PMC article.
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Among authors: webb el. Lancet Infect Dis. 2024 Mar;24(3):285-296. doi: 10.1016/S1473-3099(23)00501-7. Epub 2023 Nov 25. Lancet Infect Dis. 2024. PMID: 38012890 Free article. Clinical Trial.
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Powell Doherty R, Marshall JL, Cabrera Puig I, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Among authors: webb el. Lancet Infect Dis. 2024 Feb;24(2):e78-e79. doi: 10.1016/S1473-3099(23)00758-2. Epub 2024 Jan 3. Lancet Infect Dis. 2024. PMID: 38184003 No abstract available.
Pre-vaccination Schistosoma mansoni and hookworm infections are associated with altered vaccine immune responses: a longitudinal analysis among adolescents living in helminth-endemic islands of Lake Victoria, Uganda.
Natukunda A, Zirimenya L, Nkurunungi G, Nassuuna J, Nkangi R, Mutebe A, Corstjens PLAM, van Dam GJ, Elliott AM, Webb EL. Natukunda A, et al. Among authors: webb el. Front Immunol. 2024 Aug 29;15:1460183. doi: 10.3389/fimmu.2024.1460183. eCollection 2024. Front Immunol. 2024. PMID: 39267753 Free PMC article. Clinical Trial.
The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda (POPVAC B): a double-blind, randomised controlled trial.
Zirimenya L, Natukunda A, Nassuuna J, Nkurunungi G, Zziwa C, Ninsiima C, Kukundakwe C, Nankabirwa CM, Katushabe C, Namusobya LK, Oduru G, Kabami G, Kabali J, Kayiwa J, Kabagenyi J, van Dam GJ, Corstjens PLAM, Cose S, Wajja A, Staedke SG, Kaleebu P, Elliott AM, Webb EL; POPVAC trial team. Zirimenya L, et al. Among authors: webb el. Lancet Glob Health. 2024 Nov;12(11):e1838-e1848. doi: 10.1016/S2214-109X(24)00281-X. Lancet Glob Health. 2024. PMID: 39424572 Free PMC article. Clinical Trial.
248 results